As the life sciences sector continues to push the boundaries of scientific discovery, it must also confront unique areas of liability inherent to their work. As these corporations progress from theorising new solutions to implementing them in clinical trials, they are met with a broad array of prospective liabilities that alter fundamentally as their work descends deeper into the field of drug discovery.
According to advice from Woodruff Sawyer, even within the intricate stages of research and development, the liabilities that these companies face can morph significantly as they shift through the gears of product development.
- Pre-clinical phase companies, those undertaking rigorous testing of their novel products before entering human trials, are exposed to issues such as intellectual property disputes and insider trading accusations.
- But once the human clinical trial phase starts, these companies start assuming product liability exposure linked with unwanted side effects augmenting in the diverse human cohort. These concerns can be further complicated by differences in worldwide regulatory frameworks.
With over 500 clients within the life sciences realm, ranging from quick expanding startups to companies with international product sales and operations, Woodruff Sawyer boasts a wealth of experience in identifying these exposures and creating strategies to manage them.
Thus, while the life sciences field offers vast potential for the improvement of human health, corporations operating within this sector must exercise an abundance of caution to navigate the complexities of their unique risk profile.